TIDBSI: Low-Dose CT ScreeningFrom Survivor
Screening for lung cancer is a controversial topic among medical professionals and patients. In this segment, our intrepid Things I Do But Should I duo Paul and Justin dig deep into the guidelines so we can guide our patients through this decision.21min 1Justin McCarthy, MD and Paul Simmons, MD
Nephrogenic Systemic FibrosisFrom The Certainty of Uncertainty
We’ve talked about IV contrast and the kidneys, but what about the gadolinium-based contrast agents we use for MRIs? Are they safe in kidney disease? Neda and Paul break down nephrogenic systemic fibrosis and how we should think about the GBCAs.20min 57Neda Frayha, MD and Paul Simmons, MD
COVID CXR Study and Findings in Ambulatory PatientsFrom COVID CXR Study and Findings in Ambulatory Patients
Drs. Mike Weinstock and Josh Russell, from Urgent Care RAP, just published a landmark COVID study: CXRs obtained from confirmed and symptomatic COVID-19 patients presenting to the UC were normal in 58.3% of cases, and normal or only mildly abnormal in 89% of patients.16min 48Josh Russell, MD, Mike Weinstock, MD, and Matthew DeLaney, MD, FACEP, FAAEM
COVID: What If I Get Called In?From COVID: What If I Get Called In?
Many healthcare workers are worried if we get called in to help with COVID patients because this may be outside our scope of practice. Aaron Bright, MD sits down with Salim Rezaie, MD to simplify critical frontline lessons to keep you and your patients safe if you get called in. Topics include …30min 58Aaron Bright, MD and Salim Rezaie, MD
Breast Cancer Screening: When to Begin?From Weird and Wacky Wounds
PC RAP has covered the start-screening-mammos-at-age-50 perspective in the past. Today, we’ll explore the other side of the coin: why women’s health focused organizations recommend beginning annual screening mammography at age 40. Neda sat down with Dr. Alison Chetlen, breast imaging expert and …26min 12Alison Chetlen, DO and Neda Frayha, MD
Post-Contrast AKI: A Nephrology PerspectiveFrom Just Say No To Teratogens
Last month, Dr. Salim Rezaie and Neda got into the controversy around contrast induced nephropathy -- correction --- post-contrast AKI. This month, Dr. Swapnil Hiremath shares his perspective as a nephrologist and how, if at all, it should change our practice24min 13Swapnil Hiremath, MD MPH
Post-Contrast AKIFrom Oh, Porphyria!
Post-contrast AKI (or contrast induced nephropathy as it used to be called) is one of those hot-button issues in modern medicine. Is it really a thing? Was it ever, really? Neda sits down with Dr. Salim Rezaie of Rebel EM for an invigorating conversation about this controversial topic and what the …27min 3Salim Rezaie, MD and Neda Frayha, MD
Incidental Lung NodulesFrom This Mailbag is About to Rupture!
How often do we groan when we find incidental lung nodules on imaging? How do we know what counts as high-risk and when to re-image different patients? In this segment, Tom Robertson and Neda Frayha explore this all-too-common dilemma and share guideline-based recommendations on what to do for lung …12min 6Tom Robertson, MD